Results 41 to 50 of about 46,038 (143)

Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study

Gut and Liver, 2015
Background/AimsIn patients with corticosteroid-refractory ulcerative colitis (UC), cyclosporine or infliximab may be added to the treatment regimen to induce remission.
doaj   +1 more source

A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab early colectomy

Therapeutic Advances in Chronic Disease, 2019
Background: Early intervention for acute severe ulcerative colitis (ASUC) improves outcomes. Outcomes and healthcare costs for an infliximab-first and colectomy-first approach were compared.
Abhinav Vasudevan, Asiri Arachchi, Cian Scanlon, Jarrod Greenhalgh, Daniel R. Van Langenberg   +4 more
doaj   +1 more source

Cystoid Macular Edema: Possible Complication of Infliximab Therapy in Behçet’s Disease

Case Reports in Ophthalmology, 2010
Aim: Infliximab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, has been reported to be effective in refractory uveoretinitis in Behçet’s disease.
Junko Ikewaki, Hirofumi Kono, Kei Shinoda, Toshiaki Kubota, Kazuo Nakatsuka   +4 more
doaj   +1 more source

Outcomes of a National Cohort of Children with Acute Severe Ulcerative Colitis

Frontiers in Pediatrics, 2018
AimAll Irish children with ulcerative colitis (UC) attend the National Centre for Paediatric Gastroenterology at Our Lady’s Children’s Hospital, Crumlin. The aim of this study was to determine the outcomes of children with acute severe ulcerative colitis
Abisoye O. Akintimehin, Ríoghnach Sinead O’Neill, Conor Ring, Tara Raftery, Tara Raftery, Séamus Hussey, Séamus Hussey, Séamus Hussey   +7 more
doaj   +1 more source

Infliximab in the treatment of rheumatoid arthritis

Biologics: Targets & Therapy, 2009
A PerdrigerService de Rhumatologie, CHU de Rennes, Hôpital sud, FranceAbstract: Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis (RA).
A Perdriger
doaj  

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.

PLoS ONE
BackgroundThe Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV ...
Nimer S Alkhatib, Abdulaali R Almutairi, Majid Almadi, Shiraz Halloush, Yazed Sulaiman H Al-Ruthia, Omar Rashdan, Samah Al-Shatnawi, Nahla A Azzam, Mahmoud H Mosli, Amal M Badawoud, Majed S Al Yami, Abdulaziz Alhossan, Ibtisam AlHarbi   +12 more
doaj   +1 more source

Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy.

PLoS ONE, 2014
AimTo assess the endoscopic activity and Clinical activity after a one-year period of infliximab therapy and to evaluate the association between mucosal healing and need for retreatment after stopping infliximab in patients with Inflammatory bowel ...
Cong Dai, Wei-Xin Liu, Min Jiang, Ming-Jun Sun   +3 more
doaj   +1 more source

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

Open Access Rheumatology: Research and Reviews, 2017
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O'Sullivan M, Curran AM, Carey JJ   +8 more
doaj  

Clinical experience with infliximab administration in patients with rheumatoid arthritis by Russian register data

Терапевтический архив, 2009
Aim. To analyse the data on infliximab administration (efficacy, tolerance, toxicity) in patients with rheumatoid arthritis (RA) in Russia by clinical evidence provided by the multicenter observation trial. Material and methods. The register included 297
Galina Viktorovna Lukina, Yakov Aleksandrovich Sigidin, Evgeniy L'vovich Nasonov, G V Lukina, Ya A Sigidin, E L Nasonov   +5 more
doaj  

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update

Clinical and Experimental Gastroenterology, 2009
Garrett Lawlor, Alan C MossBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: Infliximab is a monoclonal antibody against tumor necrosis factor (TNF) which has become an established therapy for Crohn’s ...
Garrett Lawlor, Alan C Moss
doaj